Real-time Estimate
Cboe Europe
08:33:12 2024-05-13 am EDT
|
5-day change
|
1st Jan Change
|
32.14
CHF
|
-1.27%
|
|
+3.48%
|
+18.55%
|
Fiscal Period: December |
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
13,854
|
15,425
|
-
|
-
|
Enterprise Value (EV)
1 |
16,969
|
18,516
|
18,132
|
17,363
|
P/E ratio
|
179
x
|
20.9
x
|
15.6
x
|
12
x
|
Yield
|
1.4%
|
1.75%
|
2.3%
|
2.99%
|
Capitalization / Revenue
|
1.44
x
|
1.5
x
|
1.41
x
|
1.34
x
|
EV / Revenue
|
1.76
x
|
1.8
x
|
1.66
x
|
1.51
x
|
EV / EBITDA
|
9.74
x
|
9.18
x
|
7.87
x
|
6.64
x
|
EV / FCF
|
-72.5
x
|
41.5
x
|
19.1
x
|
14.8
x
|
FCF Yield
|
-1.38%
|
2.41%
|
5.24%
|
6.78%
|
Price to Book
|
1.6
x
|
1.71
x
|
1.56
x
|
1.44
x
|
Nbr of stocks (in thousands)
|
431,000
|
429,717
|
-
|
-
|
Reference price
2 |
32.14
|
35.90
|
35.90
|
35.90
|
Announcement Date
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
9,647
|
10,283
|
10,938
|
11,502
|
EBITDA
1 |
-
|
1,743
|
2,018
|
2,305
|
2,616
|
EBIT
1 |
-
|
1,488
|
1,766
|
2,035
|
2,336
|
Operating Margin
|
-
|
15.42%
|
17.17%
|
18.61%
|
20.31%
|
Earnings before Tax (EBT)
1 |
1,102
|
130
|
986.6
|
1,442
|
1,764
|
Net income
1 |
848
|
77
|
739.2
|
990.8
|
1,281
|
Net margin
|
-
|
0.8%
|
7.19%
|
9.06%
|
11.14%
|
EPS
2 |
-
|
0.1800
|
1.717
|
2.296
|
2.985
|
Free Cash Flow
1 |
-
|
-234
|
445.8
|
950.5
|
1,177
|
FCF margin
|
-
|
-2.43%
|
4.33%
|
8.69%
|
10.23%
|
FCF Conversion (EBITDA)
|
-
|
-
|
22.09%
|
41.24%
|
44.98%
|
FCF Conversion (Net income)
|
-
|
-
|
60.31%
|
95.93%
|
91.85%
|
Dividend per Share
2 |
-
|
0.4500
|
0.6282
|
0.8238
|
1.072
|
Announcement Date
|
8/18/23
|
3/13/24
|
-
|
-
|
-
|
Fiscal Period: December |
2023 S1
|
2023 Q3
|
2023 Q4
|
2023 S2
|
2024 Q1
|
---|
Net sales
1 |
-
|
2,186
|
2,543
|
4,880
|
2,492
|
EBITDA
|
-
|
-
|
-
|
751
|
-
|
EBIT
|
-
|
-
|
-
|
618
|
-
|
Operating Margin
|
-
|
-
|
-
|
12.66%
|
-
|
Earnings before Tax (EBT)
|
362
|
-
|
-
|
-
|
-
|
Net income
|
235
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
9/5/23
|
10/24/23
|
3/13/24
|
3/13/24
|
5/7/24
|
Fiscal Period: December |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
3,115
|
3,091
|
2,706
|
1,938
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
1.787
x
|
1.532
x
|
1.174
x
|
0.7407
x
|
Free Cash Flow
1 |
-
|
-234
|
446
|
951
|
1,177
|
ROE (net income / shareholders' equity)
|
-
|
11%
|
11.2%
|
13%
|
14.1%
|
ROA (Net income/ Total Assets)
|
-
|
5.15%
|
4.62%
|
5.68%
|
6.43%
|
Assets
1 |
-
|
1,494
|
15,995
|
17,449
|
19,928
|
Book Value Per Share
2 |
-
|
20.10
|
21.00
|
23.00
|
25.00
|
Cash Flow per Share
2 |
-
|
0.8400
|
3.140
|
3.150
|
3.750
|
Capex
1 |
-
|
586
|
538
|
511
|
498
|
Capex / Sales
|
-
|
6.07%
|
5.23%
|
4.67%
|
4.33%
|
Announcement Date
|
8/18/23
|
3/13/24
|
-
|
-
|
-
|
Last Close Price
35.9
USD Average target price
38.79
USD Spread / Average Target +8.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.14% | 15.43B | | +20.30% | 43.27B | | +25.28% | 22.92B | | +13.56% | 12.95B | | +43.79% | 11.83B | | -7.79% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B | | +9.14% | 4.9B |
Generic Pharmaceuticals
|